Dean H Wilson

US Patent:

8158637, Apr 17, 2012

Filed:

Nov 13, 2006

Appl. No.:

11/598576

Inventors:

Dean Wilson - Bedford MA, US
Lev T. D. Fanning - San Marcos CA, US
Paul Krenitsky - San Diego CA, US
Andreas Termin - Encinitas CA, US
Pramod Joshi - San Diego CA, US
Urvi Sheth - San Diego CA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A01N 43/54
A61K 31/517
C07D 239/72

US Classification:

5142661, 544293

Abstract:

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

US Patent:

8324220, Dec 4, 2012

Filed:

Sep 8, 2010

Appl. No.:

12/877793

Inventors:

Dean Mitchell Wilson - Bedford MA, US
Esther Ann Martinborough - San Diego CA, US
Timothy Donald Neubert - San Diego CA, US
Andreas P. Termin - Encinitas CA, US
Nicole Hilgraf - San Diego CA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/506
A61P 19/02
A61P 25/06
A61P 29/00
C07D 239/42
C07D 401/04
C07D 401/06
C07D 401/14
C07D 403/04
C07D 403/14

US Classification:

514256, 544326

Abstract:

The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

US Patent:

8329702, Dec 11, 2012

Filed:

Nov 8, 2010

Appl. No.:

12/941435

Inventors:

Dean Wilson - Bedford MA, US
Andreas Termin - Encinitas CA, US
Lev T. D. Fanning - San Marcos CA, US
Paul Krenitsky - San Diego CA, US
Pramod Joshi - San Diego CA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/497
A61K 31/445
C07D 417/00

US Classification:

51425404, 51425402, 514326, 51425213, 5462697

Abstract:

The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

US Patent:

20080167305, Jul 10, 2008

Filed:

Mar 18, 2008

Appl. No.:

12/050289

Inventors:

Dean Wilson - Bedford MA, US
Lev T.D. Fanning - San Marcos CA, US
Paul Krenitsky - San Diego CA, US
Andreas Termin - Encinitas CA, US
Pramod Joshi - San Diego CA, US
Urvi Sheth - San Diego CA, US

International Classification:

A61K 31/5377
A61K 31/517
C07D 413/14
C07D 403/14

US Classification:

5142342, 544284, 5142662, 51425217, 544120

Abstract:

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

US Patent:

20100249100, Sep 30, 2010

Filed:

Mar 29, 2010

Appl. No.:

12/748850

Inventors:

Dean Wilson - Bedford MA, US
Lev Fanning - San Marcos CA, US
Paul Krenitsky - San Diego CA, US
Joshua Boger - Concord MA, US

Assignee:

VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA

International Classification:

A61K 31/397
C07D 239/94
A61K 31/517
A61K 31/497
A61P 29/00
A61P 19/02
A61P 25/06
A61P 25/08
A61P 25/22
A61P 25/24

US Classification:

51421021, 544293, 51426622, 51425211

Abstract:

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

US Patent:

20120040935, Feb 16, 2012

Filed:

May 18, 2011

Appl. No.:

13/110173

Inventors:

Dean M. Wilson - Bedford MA, US
Andreas P. Termin - Encinitas CA, US
Timothy D. Neubert - San Diego CA, US
Jian Wang - Groton CT, US
Yulian Zhang - Yardley PA, US
Esther Martinborough - San Diego CA, US
Nicole Zimmerman - San Diego CA, US

Assignee:

Vertex Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/675
A61K 31/517
C12N 5/071
A61P 29/00
A61P 25/04
A61P 19/02
A61P 25/06
A61P 25/00
A61P 25/22
A61P 25/24
A61P 9/06
A61P 25/14
A61P 25/28
A61P 1/00
A61P 21/00
A61K 31/5377

US Classification:

514 80, 5142345, 51426622, 51425217, 5142662, 435375

Abstract:

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

US Patent:

20130183266, Jul 18, 2013

Filed:

Dec 21, 2012

Appl. No.:

13/724068

Inventors:

Vertex Pharmaceuticals Incorporated - Cambridge MA, US
Dean M. Wilson - Bedford MA, US
Laval Chan Chun Kong - Kirkland, CA
Sanjoy Kumar Das - Pierrefonds, CA
Real Denis - Laval, CA

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/381
A61K 31/7056
A61K 38/21
C07D 333/36
A61K 45/06

US Classification:

424 854, 549 69, 514447, 435184, 514 43

Abstract:

A compound is represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A biological probe comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

US Patent:

20130190289, Jul 25, 2013

Filed:

Dec 21, 2012

Appl. No.:

13/723668

Inventors:

Vertex Pharmaceuticals Incorporated - Cambridge MA, US
Dean M. Wilson - Bedford MA, US
Laval Chan Chun Kong - Kirkland, CA
Sanjoy Kumar Das - Pierrefonds, CA
Carl Poisson - Montreal, CA
John J. Court - Littleton MA, US
Qing Tang - Acton MA, US
Pan Li - Lexington MA, US
Philip N. Collier - Arlington MA, US
Nathan Waal - Cambridge MA, US
David J. Lauffer - Stow MA, US
Warren Dorsch - Providence RI, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C07D 413/12
C07D 409/12
C07D 333/38

US Classification:

51421018, 549480, 514447, 548527, 514422, 544146, 5142315, 548952, 540524, 51421208, 540488, 51421103, 435184

Abstract:

A compound is represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.